NCT05786924: Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 623 planned
- Started
- 18 Apr 2023
- Primary completion
- Jun 2028
- Arms
- Part 1A: Dose Escalation NSCLC, Part 1B: Dose Escalation GI Tumors, Part 1E: Dose Escalation Other Solid Tumors, Part 2A: Randomized Dose Optimization NSCLC, first dose level, Part 2A2: Dose Expansion NSCLC with BRAF mutations, Part 2B2: Dose Expansion CRC, Part 2B3: Dose Expansion BTC, Part 2F: Exploratory Food Effect, Part 2B4: Dose Expansion non-CRC GI Cancer, Part 2A: Randomized Dose Optimization NSCLC, second dose level
- Results
- None posted
- 28 Mar 2023: Trial registered
- 18 Apr 2023: Trial started